A novel urine test to monitor antiretroviral treatment efficacy in HIV patients

Submission date	Recruitment status No longer recruiting	Prospectively registered		
18/09/2015		<pre>Protocol</pre>		
Registration date 28/10/2015 Last Edited	Overall study status Completed Condition category	Statistical analysis plan		
		Results		
		Individual participant data		
11/06/2019	Infections and Infestations	Record updated in last year		

Plain English summary of protocol

Background and study aims

The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. HIV attacks and weakens the immune system, making it more difficult for a sufferer to fight infections. It is a highly contagious disease, through bodily fluids such as blood, semen and vaginal fluids. There is currently no cure for HIV, but there are a range of drug treatments that can allow people who are HIV positive to lead a long and full life. Antiretroviral therapy (ART) is the standard treatment for HIV, where at least three different antiretroviral (ARV) drugs are given at the same time. This treatment is very effective at supressing the virus and stopping the development of the disease. When a person has been on ART, the amount of HIV present in the blood (viral load) is reduced. After three to six months of treatment, the viral load should have fallen to undetectable levels (undetectable viral load). Currently, HIV is monitored using regular blood tests to check the viral load. This can cause patients a lot of discomfort however, as well as being time consuming and expensive. Recently, metabonomics analysis has shown promise in diagnosing diseases and monitoring drug therapy. This involves measuring the levels of chemicals that are left over after a drug has been broken down by the body (metabolites). The aim of this study is to see whether testing the amount of metabolites in urine is an effective way of monitoring of ART.

Who can participate?

HIV positive adults, currently on combination antiretroviral therapy, who have had an undetectable viral load on their last two visits to the clinic.

What does the study involve?

Ten urine samples are taken from each of the patients taking part in the study. Five of these samples are taken five days in a row, and then once every two weeks for the five remaining samples. The urine samples are then assessed in the laboratory.

What are the possible benefits and risks of participating? There is no direct benefit for the patients involved in the study. There are no risks of participating as the urine collection is non-invasive. Where is the study run from?
Wharfside clinic, St Mary's Hospital (UK)

When is the study starting and how long is it expected to run for? October 2015 to December 2020 (updated 11/06/2019, previously: April 2016)

Who is funding the study?

- 1. Imperial NIHR Biomedical Research Centre (UK)
- 2. Institute for Translational Medicine and Therapeutics (UK)

Who is the main contact? Dr Xinzhu Wang xw906@imperial.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Xinzhu Wang

Contact details

Jefferiss Research Trust Laboratories,
Variety Wing D, 2nd Floor, Wright-Fleming Institute,
Faculty of Medicine, Imperial College London, St Mary's Campus
London
United Kingdom
W2 1PG
+44 20 7594 3909
xw906@imperial.ac.uk

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Optimising metabonomic analysis to monitor combination antiretroviral therapy efficacy in urine samples from HIV patients

Study objectives

The aim of this study is to determine which platform builds the best model for assessing patient stability over a short to moderate period of time.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee London - Bromley, 04/09/2015, ref: 15/LO/1584

Study design

Single-centre observational trial

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Human immunodeficiency virus (HIV)

Interventions

Ten sequential samples are taken from each patient over the course of 10 weeks. The intrapatient variability is determined in the metabolic profiling of patients who are stable on ART with undetectable viral load over a short-med period of time using using nuclear magnetic resonance spectroscopy and liquid chromatography mass spectrometry.

Intervention Type

Other

Primary outcome(s)

Urine metabonomic profiles will be measured using proton nuclear magnetic resonance spectroscopy and liquid chromatography mass spectrometry on days 1, 2, 3, 4, 5, 15, 29, 43, 57 and 71.

Key secondary outcome(s))

N/A

Completion date

31/12/2020

Eligibility

Key inclusion criteria

- 1. At least 18 years of age
- 2. HIV positive
- 3. Currently taking combination antiretroviral therapy
- 4. Two undetectable viral loads measured in the most recent visits

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Persons who lack the capacity to consent

Date of first enrolment

01/10/2015

Date of final enrolment

01/04/2016

Locations

Countries of recruitment

United Kingdom

England

Study participating centre Wharfside clinic

St Mary's Hospital Praed Street London

United Kingdom

W2 1NY

Sponsor information

Organisation

Imperial College London

ROR

https://ror.org/041kmwe10

Funder(s)

Funder type

Research organisation

Funder Name

Imperial NIHR Biomedical Research Centre

Funder Name

Institute for Translational Medicine and Therapeutics

Alternative Name(s)

ITMAT

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Stored in repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes